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ABSTRACT  
Objective: Cystic fibrosis (CF) is a genetic disease that elicits affects throughout 
the body and is characterized by a mutation in the cystic fibrosis transmembrane 
conductance regulator (CFTR) with direct, well-documented, pulmonary function 
consequences. It has been shown a single dose of a β-agonist increases cardiac 
output (Q) and stroke volume (SV) and decreases systemic vascular resistance 
(SVR) in healthy subjects. This effect is attenuated in CF subjects; however, it is 
unknown if this decreased cardiovascular response to an inhaled drug is due to 
inherent cardiovascular deficits from CFTR mutation, receptor desensitization 
from prolonged β- agonist use, or inhibited drug delivery to the blood stream due 
to mucus buildup in the lungs. This study sought to determine the effects of 
endogenous epinephrine (EPI) and norepinephrine (NE) on cardiovascular 
function in CF, and to evaluate cardiovascular function according to CFTR 
mutation (∆F508 Ins/DEL). 
Methods: Eleven CF subjects and 27 healthy control participants completed a 
cycle ergometery test with measures of Q, SV, SVR, and HR along with plasma 
measures of EPI and NE. We compared subjects by variables of cardiovascular 
function relative to EPI and NE, and also based on genetic variants of ∆F508 
Ins/DEL.  
Results: CF subjects demonstrated significantly lower Q and SV at 50% of peak 
exercise and peak exercise than healthy subjects, and a higher SVR at rest, 50% 
of peak, and peak exercise. Additionally, CF subjects also demonstrated 
significantly lower Q and SV relative to NE at rest, however there were no 
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differences in HR relative to NE or SVR relative to EPI. When SV was stratified 
for CFTR mutation type, there were significant differences at rest, 50% of peak 
exercise, and there was a trend towards significance at peak exercise. Subjects 
with a double deletion of the ∆F508 had lower SV when compared to single 
deletion subjects. 
There were moderate and significant correlations found between EPI and SV and 
EPI and Q, but not in EPI and SVR when the study population was evaluated as 
a whole. Within the healthy group, there were significant correlations between 
EPI and SV, and EPI and Q, but none between EPI and SVR. Only correlations 
between EPI and Q were seen in the CF group.  
Conclusion: These results demonstrate that CF subjects have lower 
cardiovascular function parameters. Further, these results suggest that this 
impairment in cardiovascular function is likely the result of impairment in CFTR 
function due to CFTR genotype differences of the ΔF508, rather than receptor 
desensitization or inhibited drug delivery. 
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Cystic fibrosis (CF) is the most prevalent autosomal recessive disease in 
Caucasians, in which approximately 1 in 25 are a carrier of a known mutation for 
CF. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) 
lead to abnormal regulation of chloride (Cl-) and sodium (Na+) ions, which can 
result in an increase of viscosity and a loss volume of airway surface fluid in the 
lung [1, 2]. This change in volume and viscosity can lead to the development of 
thick, sticky mucus in the lung that is characteristic of CF in humans. Of the 
1000+ known human CFTR mutations, nearly 70% have been tied to the ∆F508 
gene [3]. Additionally, research suggests that subjects who have a homozygous 
mutation of the ∆F508 gene may demonstrate greater disease severity and lower 
pulmonary function than those who have a heterozygous ∆F508 gene mutation, 
or CF resulting from mutations in CFTR at other sites [4].  
It has been shown that mutations in CFTR play an important role in 
pulmonary function in subjects with CF, including decreases in gas and drug 
transfer ability into the bloodstream, and increases in airway obstruction and 
infection [1, 5-9]. The majority of suggested cardiovascular relationship in CF to 
date has been identified as right heart failure (cor pulmonale) and has been found 
to be secondary to obstructive lung disease related to ∆F508 gene mutations in 
these populations [10, 11]. More recently, however, it has been demonstrated that 
CFTR may also influence left ventricular cardiac function, particularly cardiac 
contractility, in cell and animal models of CF [12, 13]. Furthermore, several 
studies have suggested that there is an inherent impairment of cardiovascular 
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function in individuals with CF regardless of disease severity; however, there 
remain few studies investigating the direct effect of CFTR mutations on 
cardiovascular function in humans.  
Treatment with a β2-agonist is common in CF subjects and has been well 
documented to aid in sputum expectoration, bronchodilation, and mucus 
degradation in the lungs [14-17]. Use of a β2-agonist must be closely cycled, as 
desensitization has been known to occur as a result of prolonged use of this class 
of drugs [12, 18]. We have previously shown that the administration of a β-
agonist, results in an increase in cardiac output (Q) and stroke volume (SV), and 
a decrease in systemic vascular resistance (SVR) in healthy humans, suggesting 
systemic stimulation of the cardiovascular β-adrenergic receptors through the 
inhalation of this drug [19]. More recently we have demonstrated that this 
cardiovascular response to an inhaled β-agonist was attenuated in subjects with 
CF, which could be due to inhibited drug delivery as a consequence of mucus 
buildup, receptor desensitization due to prolonged use of a β2 agonist, or inherent 
reductions due to CFTR mutations [18].  
Therefore, the purpose of the present study was to determine the effects of 
endogenous circulating catecholamines (epinephrine and norepinephrine) on 
variables of left ventricular cardiovascular function at rest in subjects with CF 
when compared to healthy subjects. We sought to determine if the cardiovascular 
function with albuterol was attributable to inhibited drug delivery by measuring 
cardiovascular variables relative to endogenous catecholamines (which do not 
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have to pass through the lung/blood barrier to elicit function on the heart and 
vessels). Furthermore, we wanted to investigate the relationship between the 
degree of ∆F508 (Ins/DEL) gene mutation and variables of cardiovascular 
function in order to explore a relationship between CFTR mutation and inherent 
left ventricular cardiovascular function. 
A literature review as well as a following methodology, results, discussion 
and conclusions pertaining to this study are detailed in the following chapters. 
Chapter two delves into CF as a disease, the mechanistic nature of the CFTR and 
how mutations in the ∆F508 gene lead to the development of CF, as well as 
proposed mechanisms for the regulation of cardiac contractility through CFTR 
function, based on early research. Chapter three addresses the methodology of 
this study including data collection, measurement techniques, variable 
calculations, and statistical analysis of variables. Chapter four outlines and details 
the results of the present study by analyzing cardiovascular function relative to 
epinephrine and norepinephrine in CF subjects as compared to healthy subjects. 
Chapter four also outlines the comparison of cardiovascular function in CF 
subjects as stratified by CFTR ∆F508 mutation degree. Chapter five discusses the 
importance, implications, and limitations of the present study’s findings with 
references to pertinent current literature. Chapter six concludes the resulting 
study and addresses the necessity for future research on the importance of 
∆F508 mutations on cardiovascular function in CF subjects.  
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Cystic fibrosis disease   
Cystic fibrosis is an inherited autosomal recessive disease that is 
characterized by a mutation in the gene that encodes CFTR. Cystic fibrosis 
results in the abnormal function of various organ systems throughout the body, 
but the effects on the pulmonary system are particularly prominent. Mutations of 
the genes that encode for CFTR lead to altered ion regulation and are typically 
associated with abnormal regulation of chloride (Cl-) and sodium (Na+) balance [1, 
2]. As a consequence of mutations in the gene that encodes CFTR, there is a 
reduction in the volume of airway surface fluid and in increase in its viscosity, 
leading to the development of thick, sticky mucus in the lungs [2]. This debilitating 
characteristic in the pulmonary system of CF subjects can lead to increased 
incidence of lung infection and airway exacerbations, as well as functional 
impairments including increases in airway obstruction and decreases in gas and 
drug transferability into the bloodstream. [1, 20].  
While there are over 1000 known genes coding for mutations in the CFTR, 
over 70% have been tied to the ∆F508 gene [3]. Genetic research has suggested 
that homogeneity/ heterogeneity of the ∆F508 gene deletion may be related to 
disease severity, and that genotype is a more important factor than a subjects’ 
environment when assessing CF phenotype [6]. Early studies have suggested 
that subjects who have a homozygous DEL mutation of the ∆F508 gene 
demonstrate a CF diagnosis at an earlier age and a higher prevalence of 
pancreatic dysfunction than CF subjects that are heterozygous or have other 
   7 
mutations of the CFTR [7]. Furthermore, subjects that have impairments in 
pancreatic function (a common clinical problem in this patient population) also 
experienced a more severe disease prognosis, including lower pulmonary 
function [3, 7]. It remains unclear if CF subjects have inherently low cardiac 
function (for a given disease severity) or if there is a relationship between the 
degree of the ∆F508 gene mutation and cardiac function in CF subjects. 
 
CFTR ΔF508 mutations and decreases in cardiovascular function  
Although there remain few studies in vivo investigating the direct effect of 
CF and CFTR mutations on left ventricular cardiovascular function in CF 
populations, previous research has shown that CF subjects demonstrate altered 
Q, SV and SVR when compared to healthy individuals [13, 18, 21-23]. Previous 
cardiovascular work in CF patients has characterized right heart failure (cor 
pulmonale) in children and adults as a secondary disease to obstructive 
pulmonary disease [10, 11]. Several groups have shown subclinical heart 
dysfunction in CF subjects, when compared to healthy individuals, as found by 
cardiac strain, and was found independent of pulmonary function (FEV1), even in 
a relatively healthy cohort of CF subjects [23, 24]. These findings suggest an 
inherent impairment and remodeling of cardiovascular function, regardless of 
clinical disease severity. Additionally, we and others have previously 
demonstrated that individuals with CF have impaired cardiovascular function, 
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including differences in HR, Q and SV when compared to healthy subjects- 
however the mechanisms for these differences remain unknown [18, 22, 25].  
The CFTR protein is a Gs-coupled cAMP and PKA-activated protein, as 
described in brief below. When a β2 adrenergic receptor (β2 AR) is stimulated by a 
β2 agonist, (e.g. albuterol or circulating catecholamines), the stimulation travels 
through the body of the protein and lands on the Gs alpha subunit of the G-
coupled protein inside of the cell membrane. The now activated protein binds to 
and activates the enzyme adenylyl cyclase and positively stimulates the 
adenylate cyclase (AC) pathway. The AC pathway catalyzes the conversion of 
adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). An 
intracellular increase in cAMP in turn activates the cAMP dependent enzyme 
protein kinase A (PKA) to be used functionally throughout the cell. In the case of 
stimulation of a β2 AR in the lung, PKA will stimulate a portion of the binding 
domain on the CFTR and mechanically move the R Domain from blocking the 
CFTR protein. This phosphorylation disrupts the CFTR complex and leads to the 
receptor based activation of CFTR (Figure 1) [26, 27]. In epithelial cells, the 
upregulation of PKA by cAMP elevation will activate CFTR dependent chloride 
transport (increasing Cl- secretion), while at the same time inhibiting epithelial Na+ 
channel (ENaC) function (decreasing Na+ reabsorption) (Figure 1). This 
combined effect of normal CFTR on Cl- and Na+ is necessary for maintaining ion 
and fluid balance and a healthy human epithelial cell and dysfunction of this 
system is the hallmark of CF.   
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In addition to its accepted role in pulmonary function in individuals with CF, 
it is also thought that CFTR has an influence on cardiac contractility through 
alterations in cardiac myocyte function. Early studies have demonstrated that 
CFTR expression is upregulated during times of low blood flow in the plasma 
membrane of CF rat ventricular myocytes, suggesting an influence of CFTR in 
cardiac function [28]. It has been proposed that with dysfunction in the CFTR, 
there is an increase in membrane potential (due to dysfunctional ion transport) 
and a subsequent opening of L-type Ca2+ channels (LTCC) to let Ca2+ in [12]. The 
opening of LTCC increases intracellular Ca2+and inhibits PKA in favor of 
activating a pathway involving Ca2+/ calmodulin- dependent kinase II (CaMKII) to 
improve intracellular Ca2+ ion balance. CaMKII then stimulates Ca+ activated Cl- 
channels (CaCC) which work to restore the imbalance in membrane potential and 
decrease LTCC hyperactivity, effectively decreasing Ca2+ and most likely 
removing the inhibition of PKA to restore contraction rate [12]. However, recent 
work has demonstrated that in the absence of proper CFTR function, cardiac 
contractility can be maintained through the activation of CaCC, suggesting a 
correlation between normal CFTR function and cardiac contractility [12, 27-30] 
In addition to CFTR regulation of the LTCC and CaCC, it is thought that a 
cAMP dependent PKA pathway also regulates the normal functioning of the CFTR 
protein in cardiovascular tissues. Although the exact pathway is unknown, the 
major outcome of the β-AR cAMP dependent PKA pathways in cardiac tissues is 
an increase in the force and rate of ventricular contraction [12, 17, 29].   
   10 
The effect of β1 and β2-adrenergic receptors on cardiac function 
In humans, both the β1 and β2 adrenergic receptors are present in the 
heart, with the β1 receptors being the dominant form in cardiac tissue [17, 21, 31, 
32]. Several groups, have cited an approximate 75:25 ratio of β1 to β2 receptors in 
the non-failing human heart [17]. It has been shown previously that both β1 and β2 
adrenergic receptors activate the adenylate cyclase pathway in human cardiac 
myocytes, which subsequently leads to an inotropic effect from PKA and an 
increase in left ventricular cardiac contractility, as described above [17].  
Norepinephrine (NE) has been found to selectively activate β1 receptors, 
whereas epinephrine (EPI) may activate both β1 and β2 receptors with similar 
potency [33, 34]. It has been consistently shown that the positive inotropic effects 
in human cardiac myocytes by norepinephrine are mediated primarily by the 
activation of β1-adrenoceptors, and only influenced by β2-adrenoceptors at very 
high, non-physiological levels [17]. Early studies have suggested that β2 
adrenergic receptors are activated by neurotransmitters like EPI (adrenaline), and 
mediate vasodilation in peripheral vasculature and skeletal muscle tissues, 
including lung periphery, with a 10 to 30 fold higher potency than NE [17, 21, 33]. 
Previous work has shown that stimulation of β2-adrenergic receptors can lead to a 
decrease in SVR in human skeletal muscle and abdominal subcutaneous tissue; 
and further research suggests that β-adrenergic receptor activated vasodilation in 
human skeletal muscle is initiated by β2 receptors and mediated by a nitric oxide 
pathway [18, 33, 35, 36].  
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The effect of catecholamines on cardiac function  
Although the mechanisms for how β adrenergic receptor agonists influence 
the heart are unknown and largely unclassified, there remain questions as to 
which receptors, β1 or β2, have a more potent effect in cardiac myocytes [17]. 
According to one review, there are several studies to support the idea that even 
though β1 receptors are dominant in cardiac myocytes, β2 adrenergic receptors 
more selectively stimulate AC in cardiac cells, a function which is thought to be 
important in maintaining cardiac contractility [17].  
At rest, the parasympathetic nervous system dominates the regulation of 
HR in healthy humans. During exercise however, a marked increase in HR is 
attributed to sympathetic nervous system activation and parasympathetic 
withdrawal along with a noted increase in plasma norepinephrine levels [17]. 
From this, it may be considered that NE, a selective β1 agonist, induces 
increases in rate of contraction. Furthermore, infusion studies involving the use of 
both β1 and β2 agonists and inhibitors, have conclusively demonstrated that 
exercise induced increases in HR are predominantly mediated by β1 adrenergic 
receptor stimulation [17]. Infusion studies using a measure of the shortening of 
the electromechanical systole (rate and afterload independent) as a surrogate for 
measuring inotropic effects in humans have demonstrated that positive inotropic 
effects in the left ventricle are predominantly mediated by β1 adrenergic receptor 
stimulation [17]. Because of these findings, the present research used the 
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cardiovascular variables of HR, SV and Q relative to endogenous levels of NE 
when used in comparison between healthy and CF subject populations.  
 
β-receptor desensitization with chronic us of albuterol 
Suggested therapeutic treatments for CF subjects includes the use of 
physiotherapy to induce the breaking up and expectoration of sputum (mucus 
from the lungs) along with the more common inhaled aerosolized β2-adrenergic 
receptor agonists (e.g. albuterol or salmeterol) due to their bronchodilating 
characteristics in CF lungs [14-16, 37, 38]. Observations in individuals with CF 
have demonstrated that use of a β2 agonist, like albuterol, is associated with 
improvements in pulmonary function when compared to placebo after acute 
pulmonary exacerbations [14]. More recently, it has been shown that chronic use 
of a β2-adrenergic agonist may be associated with a desensitization and possible 
down-regulation of β2-adrenergic receptors in individuals with COPD and asthma 
[16, 39]. Whether or not this phenomenon of β2-receptor desensitization is related 
to or explains lower cardiovascular function in individuals with CF remains 
unknown to date.  
 
The effect of an inhaled β-agonist in cardiac function 
We have previously shown that with the administration of an inhaled β2 
agonist, there is an increase in Q and SV, and a decrease in SVR in healthy 
subjects [18]. More recently, we have found this effect to be attenuated in 
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subjects with CF [19]. Additionally, our lab has shown that variables of cardiac 
hemodynamics (cardiac power and stroke work) are also attenuated in CF 
subjects following the administration of a β2 agonist (manuscript under review).  
 
Final argument  
 Therefore, for this research, we sought to determine the effects of 
circulating endogenous catecholamines and CFTR ∆F508 mutations on 
cardiovascular function in subjects with CF. Systemic vascular resistance was 
measured relative to epinephrine (a β2 agonist), as a surrogate to measuring 
desensitization due to prolonged use of a β2 agonist (i.e. if desensitization occurs, 
we would expect to see a significant attenuation in the drop in the SVR response 
to epinephrine in individuals with CF). Furthermore, we evaluated endogenous 
catecholamines in order to eliminate the possibility of concluding that decreased 
drug permeability due to a mucus build up in CF subjects lead to the noted 
decreases in measured variables of cardiovascular function. 
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CHAPTER 3. METHODOLOGY 
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Subjects/Participants 
Eleven subjects with CF and 27 healthy control subjects completed the 
study (Table 1). Control subjects were matched for age, height, weight, and 
approximately matched for BSA and BMI- resulting in fairly well matched CF 
subjects with a relatively healthy disease prognosis. Subjects had a confirmation 
of CF using a positive sweat test (≥60.0 millimole/L Cl-) and genotyping of the 
∆F508 mutation of CFTR. Individuals with CF who presented with following 
exclusion criteria were not permitted to participate due to safety concerns: 
experienced a pulmonary exacerbation within the last two weeks or pulmonary 
hemorrhage within six months resulting in greater than 50 cc of blood in the 
sputum, were taking any antibiotics for pulmonary exacerbation, or were taking 
any experimental drugs related to CF. The Arizona Respiratory Center and its 
affiliated CF clinic at the University of Arizona Medical Center were used to recruit 
all individuals with CF. Word of mouth and posted advertising around the 
University of Arizona were used to recruit control participants. The protocol was 
reviewed and approved by the University of Arizona Institutional Review Board. 
All participants provided written informed consent prior to study, and all aspects of 
the study were performed according to the declaration of Helsinki. 
 
Testing and exercise protocol 
Subjects were asked to come in for two separate visits. The first visit 
consisted of gathering preliminary data, including subject demographics of height, 
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weight, BMI, and BSA. Additionally, at this time all CF subjects were identified 
with a positive sweat chloride test, and genotyped for the ΔF508 gene mutation- 
both of which were recorded. During this preliminary visit, subjects completed a 
VO2 max test in order to establish a baseline and familiarize the subjects with the 
protocols of pulmonary function testing during exercise, acetylene rebreathe 
during exercise, and the overall experience of completing a VO2 max test during 
an experimental protocol.  
The subjects then returned for a study visit, where data was accumulated 
and used for calculations. Upon arrival to the environmentally controlled 
physiology laboratory, participants were fitted with a 12-lead electrocardiogram 
(Marquette Electronics, Milwaukee, WI) to monitor HR, as well as an antecubital 
intravenous catheter for plasma draws throughout the exercise protocol. In a 
seated upright position, standard pulmonary function testing (i.e. flow volume 
loop: forced expiratory volume at 25 to 75% of FVC (FEF25-75), forced expiratory 
volume at 25% of FVC (FEF25), forced expiratory volume at 50% of FVC 
(FEF50), and forced expiratory volume at 75% of FVC (FEF75)) using a Medical 
Graphics CPFS system spirometer (Medical Graphics, St. Paul, MN). Spirometry 
was performed according to the guidelines of the American Thoracic Society. 
Pulmonary function testing was performed at a minimum of three times to ensure 
all measures fell within 10% of each attempt [40]. Remaining in the upright 
position, participants had systolic (SBP) and diastolic (DBP) blood pressures 
assessed using manual sphygmomanometry. Cardiac output was then assessed 
   17 
using the acetylene rebreathe technique as described previously and in brief 
below. Resting values of cardiovascular function relative to catecholamines were 
assessed in all subjects. In addition to this resting data, data was successfully 
obtained to assess relative cardiovascular function during exercise 
(cardiovascular function corrected for catecholamine levels) on 12 subjects (nine 
with CF and three healthy subjects). Measurements of Q, HR, SBP and DBP were 
completed at baseline (15min post-catheter insertion), at 50% of peak exercise 
and at peak exercise in all subjects. Additionally, at each measurement time point 
mean arterial blood pressure (MAP), SVR and SV were calculated. 
All progressive exercise tests were performed on the same cycle 
ergometer (Corival Lode B.V., The Netherlands). The testing protocol used was 
subject-specific and was based on the subject’s body size and on the type and 
intensity of the subject’s typical physical activity. The initial workload chosen also 
served as the incremental workload increase at each stage of the exercise test. 
Exhaustion of subjects was determined by an inability to maintain a pedal rate 
between 60 and 80rpm, a respiratory exchange ratio greater than 1.15, or a rating 
of perceived exertion of 18 or greater. The test ended when two out of the three 
were demonstrated, or at the subject’s request.  
 
Measurement of cardiac output 
In a seated upright position, participants breathed into a non-rebreathing 
technician-controlled pneumatic switching Y-valve (Hans Rudolph, Kansas City, 
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MO) that was connected to a pneumotachometer (Hans Rudolph, Kansas City, 
MO) and mass spectrometer (Perkin Elmer MGA-1100, Wesley, MA). The 
inspiratory port of the switching valve allowed for rapid operator controlled 
switching for breathing room air or from a 5.0 L anesthesia rebreathe bag (Hans 
Rudolph, Kansas City, MO) containing 1575 mL of test gas (0.65% acetylene 
[C2H2], 9.0% helium [He], 55.0% nitrogen, and 35.0% O2 as previously described 
[20, 41]. The timed-switching circuit and tank were calibrated and tested prior to 
each test to ensure accurate volumes, and therefore a consistent flow rate from 
the tank regularly produced the desired bag volume. Each rebreathe 
measurement period consisted of 8-10 consecutive breaths set at a cadence of 
32 breaths/min using a metronome. During each rebreathe period, individuals 
were instructed to nearly empty the bag with each inspiration while the mass 
spectrometer was used to collect serial measurement of gas concentrations 
starting at end-expiration of the first breath during the rebreathe period which 
enabled rapid calculations of Q [41]. From the lungs, acetylene disappears in the 
blood according to the rate at which pulmonary blood flow occurs, and therefore Q 
is calculated from the slope of the exponential disappearance of acetylene 
relative to the insoluble gas He [9, 41, 42]. Because Q was assessed three times 
for each participant (baseline, 30min, and 60min following albuterol 
administration), following each rebreathe period, the rebreathe bag was emptied 
with a suction device and refilled immediately prior to the next rebreathe period. 
At the start of each new rebreathe period, there was no residual gas in the dead 
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space of the apparatus, nor from the exhaled air from the participants, which was 
confirmed via gas sampling with mass spectrometer. 
 
Assessment of Cardiovascular Function 
In addition to Q and HR, variables of cardiovascular function of SV, MAP 
and SVR were calculated as follows: SV = Q/HR, MAP = DBP + 1/3(SBP – DBP), 
and SVR = MAP/Q. 
 
Assessment of Epinephrine and Norepinephrine 
Intravenous blood draws were used to assess resting endogenous 
catecholamines of EPI and NE. Levels were assessed via high-performance liquid 
chromatography at the University of Arizona pathology laboratory.  
 
Data analysis 
Independent-samples t-tests were used to compare between CF and 
healthy groups for demographic characteristics, pulmonary function/ exercise 
performance variables, and cardiovascular function variables (Q, HR, SV and 
SVR), relative to catecholamines (EPI and NE). One-way analysis of variance 
tests (one-way ANOVA) were used to analyze subjects’ cardiovascular function 
(Q, HR, SV and SVR) stratified by CFTR ∆F508 mutation code. Two-tailed 
Pearson correlation coefficients were determined for establishing relationships 
between resting levels of epinephrine and cardiovascular function (Q, SV, and 
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SVR) for three groups: CF + healthy combined, CF only, and healthy only. The 
alpha level for significance was set at p<0.05 for all tests.  
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CHAPTER 4. RESULTS 
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Subject demographics and pulmonary function variables 
Table 1 shows participant characteristics for CF and healthy subjects. 
There were no significant differences for any of the demographic characteristics 
between CF and healthy subjects, including weight, BMI and resting EPI or NE 
concentration levels. Data is presented as the mean of each group, followed by 
the standard error or number of affected participants, depending on the variable. 
This cohort of CF subjects, although retaining similar demographic variables, 
demonstrated lower pulmonary function values, as expected (Table 2). Subjects 
with CF demonstrated a lower forced expiratory volume in 1 second at rest (FEV1 
rest) as well as a lower proportion of vital capacity expired in the first second of a 
forced expiration (FEV1 / FVC rest) (p<0.01), indicating pulmonary function deficits. 
Additionally, as expected, CF subjects demonstrated a lower VO2 peak (VO2 peak), 
lower maximum wattage at VO2 MAX (Max. Watt), and lower percent predicted 
maximum wattage reached at peak exercise (WMAX %), significant at the p<0.01 
level.  
 
Cardiovascular function in CF vs. healthy 
 Cystic fibrosis subjects demonstrated significantly lower Q at 50% of peak 
exercise and peak exercise when compared to healthy subjects; as well as 
significantly lower calculated SV at rest, 50% of peak exercise and peak exercise 
as seen in Figures 3A and 3C respectively (p<0.05). Furthermore, CF subjects 
demonstrated a higher SVR at rest, 50% of peak exercise and peak exercise than 
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their healthy counterparts (Figure 4, p<0.05). When analyzed relative to resting 
levels of epinephrine and norepinephrine, CF subjects demonstrated a 
significantly lower Q and SV at rest relative to NE (Figure 5A and C respectively, 
p<0.05) however no significant differences were seen in HR relative to NE (Figure 
5B) or SVR relative to EPI (Figure 5D). Similarly, subjects who had successful 
blood sampling at rest, 50% of peak and at peak exercise demonstrated a similar 
pattern as described above relative to EPI (Figure 7), indicating that even when 
corrected for catecholamines during exercise, subjects with CF demonstrate lower 
cardiac function.  
 
Cardiovascular function and CFTR stratification 
 When CF subjects were stratified according to CFTR genotype, there were 
no statistically significant differences in Q between groups at any level of exercise 
(Figure 6A). However, there was a statistically significant difference between 
groups in HR at 50% of peak exercise (F(2, 15)= 4.182, p=0.036), but not at rest 
or peak exercise (Figure 6B). More importantly, there was a statistical significance 
in SV between groups at rest (F(2, 14)= 7.982, p<0.01), 50% of peak exercise 
(F(2, 14) =5.291, p=0.019), and approaching significance at peak exercise (F(2, 
14)=3.502, p=0.058) as shown in Figure 6C.  
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Cardiovascular function and epinephrine correlations 
 There was a moderate and significant correlation between EPI levels and 
SV (r=0.44, p<0.01) and Q (r=0.45, p<0.01), but not in EPI and SVR (r=-0.264, 
p=0.11) at rest, when considering the group as a whole (healthy and CF, Table 
3A). Within the CF group there was a significant correlation between EPI levels 
and Q (r=0.64, p<0.05) and a nearly significant correlation between EPI and SV 
(r=0.66, p=0.052), but not in SVR (r=-0.34, p=0.31) as seen in Table 3A. Within 
the healthy subject group (Table 3A), there were significant correlations between 
EPI and SV (r=0.43, p<0.05) and Q (r=0.40, p<0.05), but not in EPI and SVR (r=-
0.24, p=0.22). There was no relationship between NE and cardiac function when 
considering the group as a whole, or when considering the groups by condition 
(Table 3B). 
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 Pulmonary dysfunction attributed to CFTR mutations has been well 
documented in subjects with CF. More recently, research has demonstrated that 
CFTR may also influence cardiovascular function (specifically, cardiac 
contractility) in CF models, and has suggested that there are inherent 
cardiovascular function deficits in subjects with CF [12, 13]. We have previously 
demonstrated that there is an attenuated cardiovascular response to a β-agonist 
in subjects with CF when compared to healthy subjects [19]. The present study 
demonstrated that CF subjects had significantly lower variables of cardiovascular 
function at all three levels of exercise intensity, and differences persisted when Q 
and SV were compared relative to circulating norepinephrine. The present study 
also found significant differences in SV when CF subjects were stratified for CFTR 
genotype, the first such finding relating CFTR genotype and cardiac function in 
the human heart. Additionally, this study addresses receptor desensitization as 
there were no significant differences in SVR relative to levels of circulating 
epinephrine. If desensitization were present there would be an attenuation in SVR 
for a given epinephrine level. Collectively, these findings suggest inherent cardiac 
deficits in CF due to CFTR dysfunction.   
Our group and others have previously demonstrated decrements in 
variables of cardiovascular function including Q, SV and SVR in patients with CF, 
when compared to healthy subjects, both at rest and during exercise. While some 
groups have suggested that detriments are due to lower workloads achieved in 
patients with CF, we have found that CF subjects have an inherently lower SV 
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and Q, even for a given relative workload [19, 22]. Additionally, cardiac strain and 
strain rate echocardiography have been used to determine an influence of cardiac 
remodeling in CF, and one group has suggested that there is an inherent 
impairment and remodeling of left ventricular tissues impacting cardiovascular 
function [23, 24]. This previous work demonstrating cardiac remodeling in CF 
included a relatively healthy cohort of CF subjects displaying subclinical heart 
dysfunction, suggesting a possible direct influence of CFTR mutation on 
cardiovascular function, regardless of disease severity.  
With exercise, there is a marked increase in HR that has been attributed to 
sympathetic nervous system activation and a noted increase in plasma 
norepinephrine levels [17]. Studies with the use of both β1 and β2 agonists and 
inhibitors have conclusively demonstrated that exercise induced increases in HR 
are predominantly mediated by β1 adrenergic receptor stimulation by β1 agonists, 
that are sympathomimetic for the selective β1 agonist, norepinephrine [17]. 
Furthermore, infusion studies using a surrogate measurement for inotropic effects 
in humans, have demonstrated that positive inotropic effects in the left ventricle 
are predominantly mediated by β1 adrenergic receptor stimulation [17]. From this, 
the present research used the cardiovascular variables of HR, SV and Q relative 
to endogenous levels of NE when used in comparison between healthy and CF 
subject populations. We found that cardiac function was attenuated in patients 
with CF, despite correction for circulating catecholamines, which suggest that the 
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signaling pathway that causes this attenuation is downstream of catecholamine 
synthesis.  
The CFTR protein has been demonstrated to couple to cAMP and PKA in 
cardiac tissues, similar to the coupling systems seen in pulmonary tissues. It is 
thought that through this coupling, the major outcome of abnormal or missing 
CFTR protein function leads to an activation of a PKA pathway and an increase in 
the force and rate of ventricular contraction [12, 17, 29]. Recent work has 
suggested a specific correlation between CFTR and cardiac contractility, showing 
that there is upregulation of CaCC activity with CFTR-knockout, which is thought 
to reestablish and maintain cardiac contractility [12, 27-29]. Individuals with a 
homozygous mutation of the ∆F508 gene may exhibit greater disease severity, 
including lower pulmonary function and greater pancreatic dysfunction [4, 7, 8]. 
Based on this influence and the proposed relationship between CFTR and cardiac 
contractility, the present study stratified CF subjects according to CFTR ∆F508 
genotype in order to evaluate impairments in cardiovascular function and disease 
severity relative to the type of ∆F508 mutation, the first study to do so. Significant 
differences were seen in SV between homozygous and heterozygous groups at 
rest, 50% of peak exercise and approaching significance at peak exercise- 
suggesting a relationship between CFTR ∆F508 mutation (and, therefore, CFTR 
function) and cardiovascular dysfunction.  
Previous research has demonstrated that there are changes in ventricular 
function including significant increases in Q and SV, and decreases in SVR in 
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healthy subjects following administration of an inhaled β-agonist [18]. Additionally, 
it has been shown that among the increases in Q and SV there was an increase 
in circulating NE, suggesting a tie between endogenous NE levels and 
cardiovascular function [18]. More recently, we have shown that left ventricular 
cardiovascular stimulation with the use of a β-agonist is attenuated in CF subjects 
when compared to healthy subjects, including a lower SV and Q.  However, 
because the ability of an inhaled drug to cross the  lung/blood barrier is inhibited 
in CF, given the mucus build up common in CF lungs, it is not clear what role drug 
delivery played in this attenuated left ventricular cardiovascular response [1, 2, 
19, 22].  It is possible that cardiovascular function in response to a β-agonist is 
inhibited in CF because of receptor desensitization, due to daily use of a β-
agonist. The present work sought to eliminate inhibited drug delivery as an 
explanation by comparing Q, SV and HR relative to endogenous levels of NE 
(which does not have to pass through lung/blood barrier to elicit response) and 
desensitization by comparing SVR relative to EPI. Even when corrected for 
catecholamine levels, CF subjects demonstrated significantly lower Q and SV, 
with no changes in SVR. These results indicate that attenuated differences in left 
ventricular cardiovascular function at rest are probably not due to inhibited drug 
delivery or desensitization but may be inherent based on CFTR ΔF508 mutation.    
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 Subjects with CF demonstrated significantly lower variables of left 
ventricular cardiac function, including lower Q and lower SV when compared to 
healthy subjects. These effects were attenuated even when corrected for resting 
endogenous NE levels. There were no differences seen in HR relative to NE or 
SVR relative to EPI. Additionally, there were significant differences in SV when 
subjects were stratified according to CFTR ΔF508 genotype. These findings 
suggest that there are inherent attenuations in cardiac function, likely due to 
altered CFTR function, in subjects with CF. Based on this information, future 
areas of research include determining if other CFTR gene mutations yield left 
ventricular cardiovascular function deficits as well, and if so, do those 
cardiovascular deficits negatively impact longevity and disease prognosis of CF 
patients. 
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Table 1.  Participant characteristics (mean ± standard error or n) 
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Table 2. Pulmonary Function and Exercise Performance in CF and Healthy 
Subjects (mean ± standard error) 
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Table 3. Cardiovascular Variable and Catecholamine Correlations  
A 
 
 
 
B 
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Figure Captions 
Figure 1. CFTR and ENaC function in Healthy Lung Epithelia. In healthy lung 
tissues, the stimulation of a β2 adrenergic receptor will move a signal through 
protein and land on a Gs coupled protein. This will stimulate the AC pathway, 
which in juncture with ATP will increase intracellular cAMP. The increase in cAMP 
will increase PKA activity, which in the case of the CFTR will stimulate it to move 
the R-Domain and allow for upregulation of the activity of CFTR and the 
movement of Cl- out of the cell. Furthermore, a functioning CFTR will control the 
regulation of the ENaC, allowing for normal ion balance and movement to exist 
within the cell.   
Figure 2. CFTR and ENaC function in CF Lung Epithelia. In lung tissues of CF 
subjects, the CFTR is damaged, and PKA does not stimulate the movement of the 
R Domain, therefore movement of Cl- out of the cell in inhibited and there is a 
marked increase in intracellular Cl-. Furthermore, the protein now fails to regulate 
the movement of Na+ through the ENaC channel, increasing intracellular Na+ 
concentration. Water will diffuse to the concentration of ions, and move out of the 
interstitial space, creating thick mucus in the interstitial space due to the lack of 
water.  
Figure 3. Comparison of variables of cardiovascular function of cardiac output (A) 
[nrest =11CF, 27 healthy; n50% =11CF, 25 healthy; npeak =11CF, 27 healthy], heart 
rate (B) [nrest =10CF, 27 healthy; n50% = 10CF, 25 healthy; npeak =10CF, 27 
healthy], and stroke volume (C) [nrest =9CF, 25 healthy; n50% =9CF, 24 healthy; 
npeak =9CF, 27 healthy], for CF (dashed) vs. healthy (solid) at rest, 50%, and peak 
exercise levels. * = p<0.05 CF vs. healthy.  
Figure 4. Comparison of systemic vascular resistance for CF (dashed) vs. healthy 
(solid) at rest, 50%, and peak exercise levels [nrest =11CF, 27 healthy; n50% 
=11CF, 24 healthy; npeak =11CF, 26 healthy],  * = p<0.05 CF vs. healthy. 
Figure 5. Comparison of relative variables of cardiovascular function for CF 
(black) vs. healthy (white) at rest. Cardiac output (A) [nrest =11CF, 27 healthy], 
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heart rate (B) [nrest =11CF, 27 healthy], and stroke volume (C) [nrest =11CF, 27 
healthy] were calculated relative to norepinephrine; systemic vascular resistance 
(D) [nrest =11CF, 27 healthy] was calculated relative to epinephrine. * = p<0.05 CF 
vs. healthy. 
Figure 6. Subjects stratified by CFTR mutation type for cardiac output (A) [nrest: 
no deletion =2, single deletion=3, double deletion=14, n50%: no deletion =2, single 
deletion=3, double deletion=13; npeak: no deletion =2; single deletion=3; double 
deletion=13], heart rate (B) [nrest: no deletion =2, single deletion=3, double 
deletion=13, n50%: no deletion =2, single deletion=3, double deletion=13; npeak: no 
deletion =2; single deletion=3; double deletion=13] and stroke volume (C) [nrest: 
no deletion =2, single deletion=2, double deletion=13, n50%: no deletion =2, single 
deletion=2, double deletion=13; npeak: no deletion =2; single deletion=2; double 
deletion=13] at rest, 50% and peak exercise levels for no ∆F508 deletion (solid 
line with circles) vs. single ∆F508 deletion (single dash line with squares) vs. 
double ∆F508 deletion (double dashed with triangles). * = p<0.05 CF vs. healthy. 
Figure 7.  Comparison of cardiac function relative to catecholamine levels at rest 
and during exercise. The panels represent Q/EPI (A) [nrest =9CF, 3 healthy; n25% 
=9CF, 3 healthy; n50% =9CF, 3 healthy; npeak =9CF, 2 healthy], and SV/EPI (B) 
[nrest =6CF, 2 healthy; n25% =6CF, 2 healthy; n50% =6CF, 2 healthy; npeak =6CF, 2 
healthy], for healthy (solid) vs. CF (dashed) at baseline, 25% peak exercise, 50% 
peak exercise, and 75% peak exercise. * = p<0.05 CF vs. healthy. 
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Figure 1. CFTR and ENaC Function in Healthy Lung Epithelia 
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Figure 2. CFTR and ENaC Function in CF Lung Epithelia 
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Figure 3.  Variables of Cardiovascular Function: CF vs. Healthy 
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 Figure 4.  Systemic Vascular Resistance: CF vs. Healthy 
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Figure 5.  Relative Variables of Cardiovascular Function for Catecholamines 
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Figure 6.  Cardiovascular Function Variables Stratified by CFTR ΔF508 Mutation 
(no deletion, single deletion and double ΔF508 deletion) 
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Figure 7.  Cardiac Output (A) and Stroke Volume (B) Relative to Epinephrine 
During Exercise 
A 
 
B 
 
